Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of HKD 519,699,000, a decrease of 46% compared to HKD 961,291,000 in the previous year[2] - The cost of sales for the same period was HKD 490,029,000, resulting in a gross profit of HKD 29,670,000, compared to a gross loss of HKD 35,603,000 in the previous year[2] - The net profit attributable to the company's owners for the year was HKD 1,311,000, a significant recovery from a net loss of HKD 52,705,000 in the previous year[2] - The basic and diluted earnings per share improved to HKD 0.77 from a loss of HKD 31.10 in the previous year[2] - The company reported other income of HKD 243,000 for the year ended December 31, 2024, compared to HKD 69,000 in 2023, indicating a significant increase[32] - The net other losses for the year ended December 31, 2024, amounted to HKD 12,828,000, compared to HKD 548,000 in 2023, reflecting a substantial increase in losses[33] - The financing costs for the year ended December 31, 2024, were HKD 23,000, down from HKD 43,000 in 2023, showing a decrease in financing expenses[34] - The company reported a profit attributable to owners of HKD 1,311,000 in 2024, a significant recovery from a loss of HKD 52,705,000 in 2023[39] - The gross profit for the year was approximately HKD 29.7 million, a turnaround from a gross loss of HKD 35.8 million in 2023, resulting in a gross margin of 5.7% compared to a gross loss margin of 3.7% in the previous year[54][56] Assets and Liabilities - The company's total assets decreased to HKD 407,309,000 from HKD 478,117,000, reflecting a decline of approximately 15%[5] - Current assets were reported at HKD 386,155,000, down from HKD 451,652,000, indicating a reduction of about 14%[5] - The company's total equity increased slightly to HKD 385,570,000 from HKD 384,114,000, showing a marginal growth of 0.4%[5] - Trade receivables, net of impairment, amounted to HKD 98,746,000 in 2024, compared to zero in 2023, indicating an increase in credit sales[44] - As of December 31, 2024, the current ratio was approximately 18.1 times, up from 4.8 times in 2023[59] - Total assets as of December 31, 2024, were approximately HKD 407.3 million, down from HKD 478.1 million in 2023[59] - The company's capital debt ratio was approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023[59] - Inventory held as of December 31, 2024, was approximately HKD 188.7 million, down from HKD 329.8 million in 2023[62] - Trade receivables amounted to approximately HKD 98.7 million as of December 31, 2024, with an expected credit loss provision of approximately HKD 0.3 million[65] - Cash and cash equivalents were approximately HKD 23.3 million as of December 31, 2024, compared to HKD 19.5 million in 2023[66] - The company had no borrowings as of December 31, 2024[67] Business Operations - The company is primarily engaged in the sale of health products and electronic components, with a focus on expanding its market presence[9] - The company has focused solely on the electronic components business in 2024, with no sales from health products and food[52] - The company completed the sale of its entire interest in Hong Wang Holdings Limited on November 28, 2024[70] - The company has adopted a diversified strategy to optimize product structure and supply chain, aiming for stable business operations amid industry fluctuations[54] - The company is actively developing its healthcare business and exploring opportunities for collaboration with industry peers, focusing on various health products and foods[81] - The company aims to maintain a diversified product category and customer base strategy to uncover new business opportunities[81] - The company will monitor market changes and adjust strategies as needed to enhance profitability and resilience against risks, while striving to deliver substantial returns to investors[81] Future Outlook - The company has not yet applied any new accounting standards that are effective for the fiscal year starting January 1, 2024, which may impact future financial reporting[16] - The company is currently assessing the impact of the new Hong Kong Financial Reporting Standards on its consolidated financial statements, which may lead to significant changes in presentation and disclosure[20] - The company anticipates that the demand for ICs and NAND flash wafers will fluctuate in the second half of 2024, impacting overall pricing trends[53] - Strong demand in the smartphone and server markets is anticipated to significantly boost memory demand, with AI-enabled smart devices likely accelerating replacement cycles in the mid to long term[81] - The gradual development of advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics is expected to create new growth opportunities in the electronic components industry[81] Dividends and Shareholder Returns - The company did not recommend any dividends for the years ended December 31, 2024, and 2023[43] - The board does not recommend the payment of a final dividend for the year[75] - The basic earnings per share for the year ended December 31, 2024, will be calculated based on the profit attributable to the owners of the company and the weighted average number of ordinary shares issued[38] - The company adopted a stock option plan effective from June 27, 2024, which is valid for ten years, but no stock options have been granted under this plan to date, resulting in a zero impact on the weighted average number of shares issued this year[77] Segment Reporting - The company has identified its reportable segments based on the internal reports reviewed by the executive directors, focusing on different product lines[22] - The company has no inter-segment sales for the years ended December 31, 2024, and 2023, indicating that all revenue is generated from external customers in Hong Kong[30] - The company has not presented segment assets and liabilities as these amounts are not regularly reviewed by the chief operating decision maker for resource allocation and performance assessment[29]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 前海健康控股有限公司 主席 黃志群先生 香港，二零二五年三月十日 於本公告日期，非執行董事為黃志群先生、陳凱犇先生及陳琦先生；執行董事為 湯裕源及源自立先生; 及獨立非執行董事為李煒先生、梁振東先生及吳鴻茹女 士。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：911） 董事會會議召開日期 前海健康控股有限公司（「本公司」）董事（「董事」）組成之董事會（「董事會」） 謹此宣佈，本公司董事會會議將於二零二五年三月二十四日（星期一）舉行，以 （其中包括）批准本公司及其附屬公司截至二零二四年十二月三十一日止之經審 核財政年度業績及其刊發，並及考慮派發末期股息之建議（如有）。 承董事會命 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 正面盈利預告 本公告由前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」） 第13.09條及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義 見上市規則）作出。 董事會謹此通知本公司股東（「股東」）及潛在投資者，根據本集團截至二零二四年 十二月三十一日止年度（「本年度」）之未經審核管理帳目（「管理帳目」）之初步審閱 及董事會目前可得資料，本集團預期錄得股東應佔溢利約1,300,000港元（「預期溢 利」），跟截至二零二三年十二月三十一日止年度（「上年度」）錄得約52,700,000港元之 虧損相比，實現轉虧為盈。 本年度轉虧為盈主要是由於以下各 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） (股份代號: 911) 補充公告 有關出售事項之須予披露交易 出售事項完成後，出售事項將導致目標公司的資產和負債(主要包括重大資產和 負債) 不再合併於本公司之合併財務報表中。該解除合併將導致集團一次性出售 事項收益約為 5180 萬港元（待公司審計師進行最終審計）。 出售事項所得款項之預期用途 出售事項所得款項將用於集團的一般營運資金。 承董事會命 前海健康控股有限公司 主席 黃志群 香港，二零二四年十二月二十日 謹此提述前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 於二零二四年十二月六日就有關出售事項之須予披露交易之公告（「該公告」）。 除另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司欲進一步公開更多有關出售事項之詳細情況。 志成之附加資訊 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 有關出售事項之須予披露交易 出售事項 於二零二四年十二月六日（交易時段後），賣方（本公司一間直接全資附屬公司）與 買方（一名獨立第三方）訂立買賣協議，據此，賣方同意出售而買方同意購買銷售 股份（即目標公司的全部已發行股本），代價為10,000港元。 上市規則之涵義 由於有關出售事項之一項或多項適用百分比率超過5%但低於25%，故出售事項構 成本公司之須予披露交易並須根據上市規則第14章遵守申報及公告之規定。 出售事項 於二零二四年十二月六日（交易時段後），賣方（本公司一間直接全資附屬公司）與買 方（一名獨立第三方）訂立買賣協議，據此，賣方同意出售而買方同意購買銷售股份 （即目標公司的全部已發行股本），代價為10,000港元。 1 買賣協議 (2) 吳懿倫（作為買 ...

Qianhai Health Holdings Limited 前海健康控股有限公司 ( 於開曼群島註冊成立的有限公司） （股份代號：911） 黃志群先生 (董事會主席) 陳凱犇先生 陳琦先生 湯裕源先生 源自立先生 獨立非執行董事 李煒先生 梁振東先生 吳鴻茹女士 董事會設立三個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 黃志群先生 | | - | - | - | | 陳凱犇先生 | | - | - | - | | 陳琦先生 | | - | - | - | | 湯裕源先生 | | - | - | - | | 源自立先生 | | - | 成員 | 成員 | | 李煒先生 | | 成員 | 主席 | 主席 | | 梁振東先生 | | 成員 | 成員 | 成員 | | 吳鴻茹女士 | | 主席 | - | - | 香港，二零二四年十一月二十二日 董事名單以及角色及職能 前海健康控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） (股份代號: 911) (1) 獨立非執行董事之委任 (2) 審核委員會成員之變動 及 (3) 非執行董事之辭任 董事會宣佈，吳鴻茹女士已獲委任為獨立非執行董事及本公司審核委員會之主席，自二零二 四年十一月二十二日起生效。 董事會進一步宣布，林捷先生須參與彼之其他事務，已辭任非執行董事，自二零二四年十一 月二十二日起生效。 獨立非執行董事之委任 前海健康控股有限公司(「本公司」)董事(「董事」)會(「董事會」)欣然宣佈，吳鴻茹女士(「吳 女士」)已獲委任為獨立非執行董事，自二零二四年十一月二十二日起生效。 吳鴻茹女士 吳女士的履歷如下： 吳女士，43 歲，先前曾任職於數間國際會計師事務所，並在物業開發、餐飲服務及貿易與製造 行業的財務報告、審核、併購及首次公開發售方面擁有豐富經驗。吳 ...

Financial Performance - The group reported total revenue of approximately HKD 307.0 million from its electronic components business, a decrease from HKD 339.9 million in the previous period, primarily due to a decline in sales volume [10]. - Gross profit for the period was approximately HKD 42.9 million, compared to a gross loss of HKD 6.4 million in the previous period, indicating a successful turnaround despite lower sales volume [10]. - The group achieved a profit attributable to owners of approximately HKD 15.5 million, a significant improvement from a loss of HKD 112.1 million in the previous period [12]. - Revenue for the six months ended June 30, 2024, was HKD 306,970, a decrease of 9.7% compared to HKD 339,899 for the same period in 2023 [39]. - Gross profit for the same period was HKD 42,896, compared to a gross loss of HKD 6,419 in 2023, indicating a significant recovery [39]. - The net profit attributable to the owners of the company for the six months ended June 30, 2024, was HKD 15,548, a turnaround from a net loss of HKD 112,118 in the previous year [39]. - The electronic components segment generated revenue of HKD 306,970,000, while the health products segment reported no revenue, leading to a total revenue of HKD 306,970,000 for the first half of 2024 [50]. - The cost of sales for the electronic components segment was HKD 264,074,000, resulting in a segment performance of HKD 42,896,000, compared to a loss of HKD 6,419,000 in the same period of 2023 [50]. Loss Provisions and Expenses - The group recognized an additional loss provision of HKD 19.9 million due to unavoidable costs exceeding expected economic benefits from certain procurement contracts [11]. - A loss provision of approximately HKD 112.1 million was recorded during the interim period due to delays in fulfilling procurement contracts [22]. - The company recorded a net loss of HKD 19,868,000 in other losses for the first half of 2024, a significant reduction from a loss of HKD 99,185,000 in the same period of 2023 [53]. - Administrative expenses rose to HKD 7,406,000 in the first half of 2024, compared to HKD 6,528,000 in the same period of 2023 [50]. - The financing costs decreased to HKD 8,000 from HKD 26,000 in the same period of 2023, indicating improved cost management [54]. Assets and Liabilities - Total assets increased to HKD 525,266 as of June 30, 2024, up from HKD 478,117 as of December 31, 2023, reflecting a growth of 9.8% [40]. - Current assets rose to HKD 500,009, compared to HKD 451,652 at the end of 2023, marking an increase of 10.7% [40]. - Current liabilities increased significantly to HKD 125,457 from HKD 94,003, an increase of 33.4% [41]. - The group held inventory of approximately HKD 375.3 million as of June 30, 2024, up from HKD 329.8 million on December 31, 2023 [16]. - Prepayments for inventory purchases amounted to approximately HKD 117.5 million as of June 30, 2024, compared to HKD 102.0 million on December 31, 2023 [17]. - Trade and other receivables rose to HKD 122,352, up from HKD 102,342, reflecting a growth of 19.6% [40]. Shareholder Information - As of June 30, 2024, the company had a total of 169,445,000 issued shares, with 89,248,577 shares held by controlled corporations [24]. - The major shareholder,拓陞, holds 89,248,577 shares, representing 52.67% of the total shares [28]. - The beneficial ownership of the major shareholders includes 黃志群 with 80% and 林捷 with 20% of拓陞's shares [26]. - The company has a consistent shareholder structure with significant control by a few entities, ensuring stability in governance [28]. - The company’s issued and fully paid ordinary shares as of June 30, 2024, were 169,445 thousand shares, reflecting adjustments due to a share consolidation [68]. Corporate Governance - The audit committee consists of three independent non-executive directors, ensuring effective risk management and internal control systems [37]. - The audit committee reviewed the financial performance for the six months ending June 30, 2024, and confirmed that the interim consolidated financial statements were prepared in accordance with applicable standards and regulations [38]. - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value and accountability [35]. - The company has adopted a code of conduct for securities trading by directors, ensuring compliance with the standards set out in the listing rules [36]. Future Outlook and Investments - Future growth opportunities are anticipated in the electronic components industry driven by advancements in third-generation semiconductor materials, 5G technology, AI, and automotive electronics [13]. - The group plans to invest in production facilities in China to provide additional value-added services, including technical support and product modifications [13]. - The group will pursue business expansion opportunities through investments or acquisitions of promising businesses or projects to maximize long-term shareholder value [14]. Stock Options and Dividends - The new stock option plan was adopted on June 27, 2024, for a duration of ten years, aimed at rewarding contributions to the group's growth and attracting talent [31]. - The stock option plan aims to align the interests of participants with those of shareholders to promote long-term financial performance [31]. - The total number of stock options available for grant under the new plan as of June 27, 2024, and June 30, 2024, is 16,944,500 shares, representing approximately 10% of the company's issued share capital as of the report date [33]. - The company did not recommend any interim dividend for the period [23]. - The company did not declare any dividends for the six months ended June 30, 2024, nor for the period following the report [59].

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of HKD 306,970,000, a decrease of 9.7% compared to HKD 339,899,000 for the same period in 2023[1] - The gross profit for the same period was HKD 42,896,000, a significant improvement from a gross loss of HKD 6,419,000 in the previous year[1] - The operating profit before tax for the six months ended June 30, 2024, was HKD 15,548,000, compared to an operating loss of HKD 112,118,000 in the prior period[2] - The total comprehensive income for the period attributable to the company's owners was HKD 15,695,000, a turnaround from a loss of HKD 112,100,000 in the previous year[2] - The company reported a basic earnings per share of HKD 0.0918 for the current period, compared to a loss per share of HKD 0.662 in the previous year[2] - The group recorded total revenue of approximately HKD 307.0 million from the electronic components business, a decrease from HKD 339.9 million in the previous period, primarily due to a decline in sales volume[30] - The group reported a profit attributable to shareholders of approximately HKD 15.5 million for the interim period, a significant improvement from a loss of HKD 112.1 million in the previous period[32] Assets and Equity - The company's total assets increased to HKD 525,266,000 as of June 30, 2024, up from HKD 478,117,000 as of December 31, 2023[3] - Current assets rose to HKD 500,009,000, compared to HKD 451,652,000 at the end of 2023, indicating a growth of 10.7%[3] - The total equity attributable to the company's owners increased to HKD 399,809,000 from HKD 384,114,000, reflecting a growth of 4.1%[3] - The total assets included receivables of HKD 4,573,000 and prepayments for inventory purchases of HKD 117,513,000 as of June 30, 2024[24] - The group held inventory valued at approximately HKD 375.3 million as of June 30, 2024, an increase from HKD 329.8 million as of December 31, 2023[35] - The group’s prepayments for inventory purchases amounted to approximately HKD 117.5 million as of June 30, 2024, compared to HKD 102.0 million as of December 31, 2023[36] Operational Efficiency - The net other losses decreased significantly from HKD 99,185,000 in 2023 to HKD 19,868,000 in 2024, reflecting improved operational efficiency[14] - The segment performance for the same period in 2023 showed a loss of HKD 6,419,000, indicating a significant improvement year-over-year[12] - The group achieved a gross profit of approximately HKD 42.9 million, compared to a gross loss of HKD 6.4 million in the previous period, indicating a successful adjustment in operational strategy despite declining sales[30] Investments and Future Plans - The company is primarily engaged in the sale of electronic components and health products, indicating a focus on these sectors for future growth[5] - The group plans to invest in production facilities in China to provide additional value-added services, including technical support and product modification[33] - The group anticipates significant growth in the new energy sector, including electric vehicles and photovoltaic energy storage systems, which is expected to drive demand for related electronic products[33] Legal and Compliance - The company has undergone a share consolidation effective May 20, 2024, resulting in a legal capital of HKD 200 million divided into 500 million shares, of which 169,445,000 shares are issued and fully paid[40] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim financial statements and confirmed they are prepared in accordance with applicable standards and regulations[48] - The company is currently seeking legal advice regarding ongoing litigation matters and will monitor their potential impact closely[41] Dividends and Shareholder Returns - The company did not declare any dividends for the six months ended June 30, 2024, nor for the period following the report[20] - The board of directors does not recommend the payment of any interim dividend for the period[45] Risks and Liabilities - The group has no significant contingent liabilities as of June 30, 2024[42] - The group has not encountered any significant foreign exchange risks due to its monetary assets and liabilities being primarily denominated in HKD and USD[39] - During the interim period, the group recorded a loss provision of approximately HKD 112.1 million due to delays in the performance of procurement contracts[41]

Qianhai Health Holdings Limited 前海健康控股有限 公 司 （於開曼群島註冊成立之有限公司） （股份代號: 911） 2023 年報 2023 ANNUAL REPORT (Stock Code: 911) 前海健康控股有限 公 司 (Incorporated in the Cayman Islands with limited liability) Qianhai Health Holdings Limited Qianhai Health Holdings Limited 前海健康控股有限 公 司 Annual Report 2023 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 管理層討論與分析 | 4 | | 董事及高級管理層之履歷詳情 | 9 | | 企業管治及其他資料 | 13 | | 董事會報告 | 25 | | 環境、社會及管治報告 | 39 | | 獨立核數師報告 | 50 | | 綜合損益表 | 56 | | 綜合全面收益表 | 57 | | 綜合財務狀況表 | 58 | | 綜合權益變動表 | 60 | | 綜合現 ...